Tags

Type your tag names separated by a space and hit enter

Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.
Int J Cancer. 2010 Jul 01; 127(1):111-7.IJ

Abstract

High-risk human papillomavirus types (HPV-HR) are associated with head and neck cancer (HNC) risk and better survival. Most patients with HPV-HR DNA-positive tumors develop anti-HPV E6/E7 antibodies; however, it is unclear whether those who mount an immune response have similar risk factors or clinical outcomes as those who do not. HPV-16 DNA tumor-positive HNC cases were evaluated for HPV-16 E6 and E7 antibodies using a GST capture ELISA system. Among 57 HPV-16 DNA tumor-positive HNC cases, 67% were detected with HPV-16 E6 and/or E7 antibodies. Male gender (76% vs. 42%, p = 0.02), younger age (63% vs. 16%, p = 0.001) but not tobacco or alcohol were associated with E6 and/or E7 seropositivity. Seropositivity was associated more often with late stage (76%), poor grade (65%), positive nodes (82%). and in the oropharynx (82%), Median disease-specific and recurrence-free survival were longer in E6 and/or E7 seropositive compared to E6/E7-negative cases (2.2 years vs. 1.4 years, both outcomes), although results were not statistically significant. When examined jointly with p16 expression, E6 and/or E7-positive/p16-positive cases had better disease-specific (2.1 years vs. 1.1 years, p = 0.06) and recurrence-free (2.3 years vs. 1.1 years, p = 0.03) survival compared to E6-/E7-/p16- cases. These findings suggest there are 2 distinct HNC patient groups with HPV DNA-positive tumors, distinguishable by E6 and/or E7 antibody status. Differences in antibody status are associated with distinct risk factors and clinical outcomes. This information can be available as a simple blood test at initial presentation, before the removal of tissue through biopsy or surgery.

Authors+Show Affiliations

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA. elaine-smith@uiowa.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

19876924

Citation

Smith, Elaine M., et al. "Risk Factors and Survival By HPV-16 E6 and E7 Antibody Status in Human Papillomavirus Positive Head and Neck Cancer." International Journal of Cancer, vol. 127, no. 1, 2010, pp. 111-7.
Smith EM, Pawlita M, Rubenstein LM, et al. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer. 2010;127(1):111-7.
Smith, E. M., Pawlita, M., Rubenstein, L. M., Haugen, T. H., Hamsikova, E., & Turek, L. P. (2010). Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. International Journal of Cancer, 127(1), 111-7. https://doi.org/10.1002/ijc.25015
Smith EM, et al. Risk Factors and Survival By HPV-16 E6 and E7 Antibody Status in Human Papillomavirus Positive Head and Neck Cancer. Int J Cancer. 2010 Jul 1;127(1):111-7. PubMed PMID: 19876924.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. AU - Smith,Elaine M, AU - Pawlita,Michael, AU - Rubenstein,Linda M, AU - Haugen,Thomas H, AU - Hamsikova,Eva, AU - Turek,Lubomir P, PY - 2009/10/31/entrez PY - 2009/10/31/pubmed PY - 2010/6/15/medline SP - 111 EP - 7 JF - International journal of cancer JO - Int. J. Cancer VL - 127 IS - 1 N2 - High-risk human papillomavirus types (HPV-HR) are associated with head and neck cancer (HNC) risk and better survival. Most patients with HPV-HR DNA-positive tumors develop anti-HPV E6/E7 antibodies; however, it is unclear whether those who mount an immune response have similar risk factors or clinical outcomes as those who do not. HPV-16 DNA tumor-positive HNC cases were evaluated for HPV-16 E6 and E7 antibodies using a GST capture ELISA system. Among 57 HPV-16 DNA tumor-positive HNC cases, 67% were detected with HPV-16 E6 and/or E7 antibodies. Male gender (76% vs. 42%, p = 0.02), younger age (63% vs. 16%, p = 0.001) but not tobacco or alcohol were associated with E6 and/or E7 seropositivity. Seropositivity was associated more often with late stage (76%), poor grade (65%), positive nodes (82%). and in the oropharynx (82%), Median disease-specific and recurrence-free survival were longer in E6 and/or E7 seropositive compared to E6/E7-negative cases (2.2 years vs. 1.4 years, both outcomes), although results were not statistically significant. When examined jointly with p16 expression, E6 and/or E7-positive/p16-positive cases had better disease-specific (2.1 years vs. 1.1 years, p = 0.06) and recurrence-free (2.3 years vs. 1.1 years, p = 0.03) survival compared to E6-/E7-/p16- cases. These findings suggest there are 2 distinct HNC patient groups with HPV DNA-positive tumors, distinguishable by E6 and/or E7 antibody status. Differences in antibody status are associated with distinct risk factors and clinical outcomes. This information can be available as a simple blood test at initial presentation, before the removal of tissue through biopsy or surgery. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/19876924/Risk_factors_and_survival_by_HPV_16_E6_and_E7_antibody_status_in_human_papillomavirus_positive_head_and_neck_cancer_ L2 - https://doi.org/10.1002/ijc.25015 DB - PRIME DP - Unbound Medicine ER -